The cellular health screening market will power at a rate of 9.7% by the end of this decade, to reach USD 5,512.8 million by 2030.
 |
| To learn more about this report: https://bit.ly/3soV7Yj |
This has a lot to do with the growing use of cellular health screening in personalized medicine, detecting ailments early, supporting in preventive care, and identification of diverse health problems; the growing count of awareness campaigns; the increasing acceptance of telomere performance programs; and the growing prevalence of chronic ailments mainly cancer globally.
The single-test panel category held a major share of the industry. This is because of its labor efficiency, affordability, and increased possibility for automation. Amongst single-panel tests, the requirement for telomere single-panel tests is will grow at the highest rate by the end of this decade. This is due to the fact that these offer precise info, aid in measurement of the length of telomere, and help in the determination of the age of cell.
North America led the cellular health screening market, and this trend will continue by the end of this decade, with USD 2.5 billion. This is because of the growing government funding for preventive healthcare, the increasing acceptance of novel technologies, the mounting consciousness about personalized medicine, and the expanding incidence of infectious and chronic diseases.
The U.S. is the leading the industry in North America, and it will grow at a rate of 10% by the end of this decade. This because of the robust healthcare infra and the existence of a numerous key players.
Europe is growing at a considerable rate. This is because of the growing elderly population, the growing incidences of chronic ailments, and the surging acceptance of cutting-edge screening methods for effective treatment of various diseases.
Due to the increasing focus toward a healthy life expectancy, the demand for cellular health screening solution will continue to grow.
